InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
67,350.64
(
0.95%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 107193

Wednesday, 11/10/2010 8:32:01 AM

Wednesday, November 10, 2010 8:32:01 AM

Post# of 252642
VRTX adds ribavirin arm to VX-222/Telaprevir all-oral HCV trial:

http://finance.yahoo.com/news/Vertex-Announces-Plans-to-bw-130493646.html?x=0&.v=1

The trial with the new ribavirin arm is the one where VRTX recently dropped the lowest dose of VX-222 due to viral breakthrough (#msg-55917569).

VRTX’s decision to add ribavirin is in sync with BI, who is already using ribavirin in its combination study of BI 201335 and BI 207127 (#msg-56271789).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up